Communiqués Arvinas, Inc.

Actions

ARVN

US04335A1051

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:37:14 25/09/2026			Varia. 5j.	Varia. 1 janv.
7,690 ^USD	-1,28%		-8,44%	-36,00%

16/09	Transcript : Arvinas, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 09:15 AM
10/08	Le traitement Casdatifan d'Arcus Biosciences pourrait être lancé en 2028, selon Morgan Stanley	MT

Communiqués

03/09	Arvinas to Participate in Upcoming Investor Conferences	GL
01/09	Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
05/08	Arvinas : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
04/08	Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update	GL
28/07	Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026	GL
05/06	Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease	AQ
04/06	Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease	GL
04/06	Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease	AQ
29/05	Arvinas to Present at Jefferies Global Healthcare Conference	GL
18/05	Arvinas Employees Give Back During Company-wide Impact Day	GL
12/05	Arvinas : Corporate Presentation – May 2026	PU
12/05	Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
12/05	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)	GL
05/05	Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026	GL
01/05	Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer	GL
18/03	Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days	GL
12/03	Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	AQ
11/03	Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders	GL
24/02	Arvinas : Corporate Presentation – February 2026	PU
24/02	Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	GL
23/02	Arvinas to Participate in Upcoming Investor Conferences	GL
19/02	Arvinas : Initial Statement of Beneficial Ownership (Form 3)	PU
17/02	Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026	GL
17/02	Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026	AQ
12/02	Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director	GL